Panreactive Antibody Screen in a Recently Transfused Patient with Anemia
A 54-year-old woman is admitted with melena and fatigue. Hemoglobin is 6.8 g/dL, platelets 210 x 10^9/L, WBC 7.4 x 10^9/L. She received 2 units of packed red cells 3 weeks ago during an outpatient endoscopy. Current specimen: group A, Rh-positive; antibody screen 3+ in all three screening cells by gel IAT; autocontrol 3+. DAT polyspecific 3+, anti-IgG 3+, anti-C3d negative. An eluate from her red cells reacts 3+ with every panel cell tested, including her own cells. Total bilirubin 2.9 mg/dL (indirect 2.4), LDH 410 U/L, haptoglobin less than 10 mg/dL, reticulocytes 9.2%. The hospitalist orders 2 more units of red cells and asks the blood bank to 'finish the workup first.'
1. Interpret the serologic and hemolytic findings. What is the next serologic step, and why is autoadsorption unacceptable in this patient?
Read the worked answer
Interpretation. A panreactive screen with a matching 3+ autocontrol, a 3+ IgG DAT, a panreactive eluate (reactive with autologous cells), plus low haptoglobin, elevated LDH and indirect bilirubin, and reticulocytosis all point to a warm autoantibody causing warm autoimmune hemolytic anemia.
Why autoadsorption fails here. She was transfused 3 weeks ago, so donor red cells are still circulating. If her plasma were adsorbed onto her own (mixed patient/donor) cells, any underlying alloantibody directed at a donor antigen would be removed along with the autoantibody. The adsorbed plasma would then look nonreactive and the alloantibody would be missed, with a hemolytic transfusion reaction as the consequence.
Next step: allogeneic (differential) adsorptions. Select 3 phenotyped donor cells (e.g., R1R1, R2R2, rr) so that, between them, common antigens are represented. Adsorb the patient's plasma separately with each cell, then test each adsorbate against a full panel. Reactivity that survives adsorption indicates an alloantibody. Phenotype or, preferably, genotype the patient's red cells, since phenotyping is unreliable after recent transfusion and in the presence of a positive DAT.
2. The clinician insists on waiting for the completed workup. How do you respond, and how do you choose units?
Read the worked answer
Do not delay transfusion. Symptomatic anemia at 6.8 g/dL is a life-threatening indication; there is no evidence that transfusing crossmatch-incompatible units in autoimmune hemolytic anemia worsens outcome when transfusion is truly needed. The workup proceeds in parallel, not in series.
Unit selection.
- Crossmatch units by IAT (gel or tube) and select crossmatch-compatible units if any exist. In warm autoantibody, many or all units may be incompatible.
- If none are compatible, give the least incompatible units - those with the weakest reaction, with preference for units that also lack antigens matching any alloantibody found after allogeneic adsorption.
- Until the adsorption is complete, consider prophylactic matching for Rh (D, C, c, E, e) and Kell, which prevents the most common and most immunogenic alloantibodies.
- Transfuse slowly with careful monitoring, and assess post-transfusion hemoglobin, bilirubin, and LDH to distinguish expected autoantibody-mediated red cell survival from a hemolytic reaction.
Document the least-incompatible selection and the clinical discussion; the clinician, not the blood bank, accepts the risk of the transfusion.
3. How would your approach change if she had no transfusion history in the past 3 months?
Read the worked answer
Autoadsorption would become the method of choice. Without circulating donor cells, the patient's own cells carry only her own antigens, so autoadsorption removes the autoantibody while leaving any alloantibody intact in the adsorbed plasma. It is more sensitive than allogeneic adsorption because there is no risk that a donor cell used for adsorption happens to carry the antigen corresponding to the alloantibody.
Practical consequences.
- Fewer adsorption steps and no need to source and phenotype donor cells, so the workup finishes faster.
- Allogeneic adsorption, by contrast, always carries a small false-negative risk for antibodies against high-prevalence antigens, since no three donor cells can represent every low-frequency/high-incidence combination.
- Even with autoadsorption, if the autocontrol and eluate remain panreactive and no alloantibody is found, the patient is still managed as warm autoimmune hemolytic anemia with least-incompatible transfusion, and the same Rh/Kell matching logic applies.